Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 11 Osteoporosis 8 Colorectal Neoplasms 4 Bone Diseases, Metabolic 4 Prostatic Neoplasms 3 Pain 3 Vitamin D Deficiency 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Lymphoma 2 Leukemia 2 Colonic Neoplasms 2 Urinary Bladder Neoplasms 1 Ureteral Neoplasms 1 Polycystic Ovary Syndrome 1 Pancreatic Neoplasms 1 Paclitaxel-induced Neuropathy 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Myocardial Ischemia 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Multiple Endocrine Neoplasia Type 1 1 Motor Activity 1 Lung Neoplasms 1 Kidney Neoplasms 1 Inflammation 1 Heart Diseases 1 Head and Neck Neoplasms 1

Interventions

Cyclophosphamide 22 blinatumomab 18 Cytarabine 15 fludarabine 13 Azacitidine 12 venetoclax 10 fludarabine phosphate 10 Rituximab 8 Lenalidomide 7 Dexamethasone 7 Methotrexate 6 Daunorubicin 6 Mercaptopurine 5 daratumumab 4 Whole-Body Irradiation 4 Vincristine 4 Melphalan 4 Idarubicin 4 Etoposide 4 Busulfan 4 pembrolizumab 3 obinutuzumab 3 Radiotherapy 3 Maintenance 3 Immunotherapy, Adoptive 3 Imatinib Mesylate 3 Granulocyte Colony-Stimulating Factor 3 Drug Therapy 3 Cladribine 3 Asparaginase 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neoplasm, Residual × Calcium × Clear all

NCT00172068 2009-12-23

MRD-1

Novartis

Phase 2 Terminated

Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡